REMARKS

Claims 1-17 are pending in the present application. The Examiner's indication that dependent claims 10-12 and 15-17 are allowable if rewritten in independent form is appreciated.

It is respectfully submitted that the present response presents no new issues or new matter and places this case in condition for allowance. Reconsideration of the application in view of the above-amendments and the following remarks is requested.

I. The Rejection of Claims 1-9, 13 and 14 under 35 U.S.C. 112, Enablement

Claims 1-9, 13 and 14 are rejected under 35 U.S.C. 112, as lacking enablement. Applicants respectfully traverse the rejection.

The claimed invention is directed to methods for starch processing using a new glucoamylase enzyme isolated from *Talaromyces emersonii* (the amino acid sequence of this new enzyme is shown in SEQ ID NO:7) and to highly related enzymes, i.e., those glucoamylases having at least 80% identity with the glucoamylase of SEQ ID NO:7. The glucoamylases recited in the claims are of the same scope as the glucoamylases patented in U.S. Patent Nos. 6,620,934 and 6,255,084. It is respectfully submitted that an artisan is enabled to practice the claimed invention. Applicants disclose both the protein sequence (SEQ ID NO:7) and nucleic acid sequence (SEQ ID NO:6) of the new glucoamylase. Using standard mutagenesis techniques known in the art for preparing new sequences, an artisan would then be able to prepare glucoamylase of the scope recited in the claims for use in the claimed method.

For the foregoing reasons, Applicants submit that the claims overcome this rejection under 35 U.S.C. 112. Applicants respectfully request reconsideration and withdrawal of the rejection.

II. Conclusion

In view of the above, it is respectfully submitted that all claims are in condition for allowance. Early action to that end is respectfully requested. The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application.

Respectfully submitted,

Date: November 17, 2004

Jasen I. Garbell, Reg. No. 44,116 Novozymes North America, Inc. 500 Fifth Avenue, Suite 1600 New York, NY 10110 (212)840-0097